wild type

(redirected from Wild-type)
Also found in: Dictionary, Thesaurus, Medical.

wild type

[′wīld ‚tīp]
(genetics)
The most prevalent allele or character in the wild organism.
References in periodicals archive ?
Wild-type MERSCoV was detected in the index patient (P001) on May 19, 2015; however, the I529T mutation was observed 3 days later (May 22, 2015), suggesting that the I529T mutation emerged within 11 days after symptom onset.
Wild-type and GLCCI1 knockout ( GLCCI1 -/-) C57BL/6N female mice of 6-8 weeks old weighing 18-20 g were bred under specific-pathogen-free conditions in the Experimental Animal Center of Central South University, Changsha, Hunan, China.
For gyrA wild-type infections, UCLA Health recommends 500 mg oral ciprofloxacin.
The researchers found that, compared with matched wild-type controls, the BRCA1/BRCA2 mutations correlated with significantly inferior median OS (20.2 versus 27.8 months) and DFS (8.4 versus 16.7 months).
Specifically, retinal thickness was reported to be similar between Akita and wild-type mice by evaluating retinal thickness at localized regions using commercial software designed for human image analysis [37, 70].
The cochleae from Myo3a mutant and wild-type mice were removed, fixed with 4% formaldehyde in 10 mM phosphate buffer at 4[degrees]C overnight, decalcified in 10% EDTA in 10 mM phosphate-buffered saline (PBS) at room temperature for 2 d, dehydrated with 30% to 100% ethanol series, and treated with xylene for transparency.
scientists have presented data from preclinical studies involving H3B-6545, an oral, selective small molecule covalent antagonist of wild-type and mutant estrogen receptor (ER) in a poster session at the San Antonio Breast Cancer Symposium (SABCS) annual meeting, the company said.
Our study identified in this patient sample a single-nucleotide polymorphism (SNP) that prevented proper binding of our wild-type probe to its cognate wild-type allele.
The complete approval for Vectibix as a treatment for patients with wild-type KRAS mCRC was based on results from the Phase 3 PRIME and ASPECCT trials.
All clinical features of these patients were retrospectively analyzed and it was concluded that patients with IDH1 mutation had longer PFS (Hazards Regression HR = 0.110, P < 0.001).6 In 2012, Yan et al.,7 also reported significantly longer PFS for GBM patients with IDH1 mutation compared to wild-type IDH1.
Compared with that of their wild-type littermates, CathA mice took significantly less time to reenter the dark compartment on the test day at 3 months (wild-type: 300 s; [CathA.sup.S190A]: 213.96 s [+ or -] 27.48; p = 0.02; n = 6 for both conditions), 6 months (wild-type: 300 s; [CathA.sup.S190A]: 236.08 [+ or -] 29.46 s; p = 0.04; n = 8 for both conditions), and 12 months of age (wild-type: 300 s; [CathA.sup.S190A]: 207.25 [+ or -] 46.93 s; p = 0.04, n = 8 for both conditions).
In the present study, we tried to address the question of whether proteasomal inhibitor MG132 can prevent diabetic nephropathy model in wild-type and Nrf2-KO mice induced by multiple low-dose streptozotocin.